Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 05, 2020 | Director, Chairman & CEO | Other acquisition or disposition | Form 4 | -- | -- | 64,895 | |
| Aug 05, 2020 | Principal Accounting Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 198 | $10.04 | 17,333 | |
| Aug 05, 2020 | Principal Accounting Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 198 | $15.05 | 17,135 | |
| Aug 05, 2020 | Principal Accounting Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 198 | -- | 5,742 | |
| Aug 17, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $5.13 | 880,713 | |
| Aug 17, 2020 | Director, Chairman & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 20,000 | $14.89 | 860,713 | |
| Aug 17, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 62,485 | |
| Aug 17, 2020 | Principal Accounting Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,181 | -- | 65,109 | |
| Aug 19, 2020 | Director, Chairman & CEO | Other acquisition or disposition | Form 4 | -- | -- | 64,895 | |
| Aug 31, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 28,750 | $6.10 | 191,954 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.